News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
727,902 Results
Type
Article (44048)
Company Profile (312)
Press Release (683542)
Multimedia
Podcasts (73)
Webinars (13)
Section
Business (211885)
Career Advice (2100)
Deals (36400)
Drug Delivery (100)
Drug Development (82311)
Employer Resources (176)
FDA (16740)
Job Trends (15322)
News (356193)
Policy (33417)
Tag
Academia (2708)
Accelerated approval (5)
Adcomms (20)
Allergies (89)
Alliances (52472)
ALS (90)
Alzheimer's disease (1403)
Antibody-drug conjugate (ADC) (135)
Approvals (16742)
Artificial intelligence (283)
Autoimmune disease (22)
Automation (16)
Bankruptcy (365)
Best Places to Work (11931)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (221)
Bladder cancer (80)
Brain cancer (27)
Breast cancer (282)
Cancer (2289)
Cardiovascular disease (177)
Career advice (1758)
Career pathing (31)
CAR-T (160)
Cell therapy (440)
Cervical cancer (19)
Clinical research (66794)
Collaboration (869)
Compensation (540)
Complete response letters (19)
COVID-19 (2675)
CRISPR (45)
C-suite (251)
Cystic fibrosis (104)
Data (2233)
Decentralized trials (2)
Denatured (30)
Depression (44)
Diabetes (272)
Diagnostics (6638)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (101)
Drug shortages (27)
Duchenne muscular dystrophy (94)
Earnings (88275)
Editorial (36)
Employer branding (22)
Employer resources (151)
Events (117382)
Executive appointments (748)
FDA (18030)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (780)
Gene editing (113)
Generative AI (26)
Gene therapy (317)
GLP-1 (728)
Government (4518)
Grass and pollen (5)
Guidances (67)
Healthcare (19540)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (116)
Indications (30)
Infectious disease (2820)
Inflammatory bowel disease (141)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (100)
Interviews (323)
IPO (16852)
IRA (41)
Job creations (3819)
Job search strategy (1496)
Kidney cancer (10)
Labor market (38)
Layoffs (480)
Leadership (18)
Legal (8128)
Liver cancer (77)
Lung cancer (324)
Lymphoma (156)
Machine learning (7)
Management (62)
Manufacturing (312)
MASH (68)
Medical device (14112)
Medtech (14117)
Mergers & acquisitions (20105)
Metabolic disorders (695)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (92)
Neuropsychiatric disorders (27)
Neuroscience (1947)
NextGen: Class of 2025 (6845)
Non-profit (4618)
Now hiring (39)
Obesity (367)
Opinion (218)
Ovarian cancer (75)
Pain (88)
Pancreatic cancer (84)
Parkinson's disease (150)
Partnered (21)
Patents (242)
Patient recruitment (113)
Peanut (49)
People (59543)
Pharmaceutical (69)
Pharmacy benefit managers (18)
Phase I (20966)
Phase II (29388)
Phase III (21814)
Pipeline (1211)
Policy (140)
Postmarket research (2582)
Preclinical (9003)
Press Release (71)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (265)
Rare diseases (386)
Real estate (6235)
Recruiting (65)
Regulatory (22868)
Reports (46)
Research institute (2460)
Resumes & cover letters (362)
Rett syndrome (5)
RNA editing (5)
RSV (43)
Schizophrenia (71)
Series A (137)
Series B (86)
Service/supplier (15)
Sickle cell disease (53)
Special edition (14)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3841)
State (2)
Stomach cancer (13)
Supply chain (69)
Tariffs (40)
The Weekly (41)
Vaccines (720)
Venture capitalists (42)
Weight loss (240)
Women's health (36)
Worklife (16)
Date
Today (206)
Last 7 days (918)
Last 30 days (2700)
Last 365 days (33636)
2025 (10980)
2024 (36228)
2023 (41143)
2022 (52406)
2021 (56997)
2020 (55613)
2019 (48409)
2018 (36445)
2017 (33548)
2016 (33152)
2015 (39368)
2014 (32952)
2013 (28003)
2012 (30257)
2011 (30877)
2010 (28835)
Location
Africa (760)
Alabama (54)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (40549)
Australia (6749)
California (6247)
Canada (2028)
China (536)
Colorado (273)
Connecticut (285)
Delaware (155)
Europe (88744)
Florida (919)
Georgia (216)
Idaho (60)
Illinois (559)
India (26)
Indiana (315)
Iowa (11)
Japan (165)
Kansas (107)
Kentucky (25)
Louisiana (11)
Maine (62)
Maryland (906)
Massachusetts (4717)
Michigan (241)
Minnesota (401)
Mississippi (2)
Missouri (88)
Montana (30)
Nebraska (25)
Nevada (64)
New Hampshire (69)
New Jersey (1761)
New Mexico (28)
New York (1774)
North Carolina (1018)
North Dakota (9)
Northern California (2712)
Ohio (209)
Oklahoma (15)
Oregon (37)
Pennsylvania (1393)
Puerto Rico (13)
Rhode Island (34)
South America (1154)
South Carolina (23)
South Dakota (1)
Southern California (2344)
Tennessee (103)
Texas (921)
United States (23702)
Utah (187)
Virginia (149)
Washington D.C. (62)
Washington State (569)
West Virginia (3)
Wisconsin (57)
727,902 Results for "myos rens technology inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
March 27, 2024
·
5 min read
Policy
MYOS RENS Technology Inc. Announces Settlement of Litigation with RENS Technology Inc.
MYOS RENS Technology Inc. (“MYOS” or the “Company”) (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced that it has settled its pending litigation with RENS Technology Inc. and its president,
July 16, 2020
·
6 min read
Press Releases
Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology
April 16, 2025
·
4 min read
Pharm Country
DC Medicaid Becomes the First Medicaid Plan to Cover the Nerivio® REN Wearable, a Non-Drug Treatment for Migraine
Theranica, a neuromodulation therapeutics company, today announced DC Medicaid’s coverage of the Nerivio® REN wearable, the first and only FDA-cleared, non-drug, non-disruptive treatment for both acute attacks and prevention of migraine with or without aura in adolescents and adults ages 12 and older.
May 21, 2024
·
4 min read
Press Releases
FOXO TECHNOLOGIES INC. ANNOUNCES EXECUTION OF A NON BINDING AGREEMENT TO ACQUIRE VECTOR BIOSOURCE INC.
March 20, 2025
·
4 min read
Press Releases
Healthcare Integrated Technologies Inc. Announces Corporate Name Change to SafeSpace Global Corporation and Ticker Symbol Update
April 24, 2025
·
2 min read
Deals
MedAvail and MYOS RENS Technology Announce Closing of Business Combination
MedAvail, Inc. (“MedAvail”), a leading technology-enabled pharmacy organization that embeds pharmacy services directly into clinics and other points of care through its proprietary technology, announced the completion of its previously announced business combination with MYOS RENS Technology, Inc. (NASDAQ: MYOS), an adva
November 18, 2020
·
5 min read
Press Releases
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary
March 13, 2025
·
5 min read
Press Releases
FOXO TECHNOLOGIES INC. PROVIDES UPDATE ON ITS BEHAVIORAL HEALTH SUBSIDIARY, MYRTLE RECOVERY CENTERS, INC.
March 12, 2025
·
3 min read
Press Releases
Kronos Advanced Technologies Inc. ($KNOS) Confirms Ownership and Shareholder Updates for KronosMD, Inc.
January 27, 2025
·
13 min read
1 of 72,791
Next
